Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Top 10 Most Recent Blog Posts
Nikola Corporation (NKLA): A Comprehensive Overview
Category: Stocks Total Views: 66By : Editor Updated: 06-01-2024
Cryptocurrency Investments: What to Expect in June 2024
Category: Crypto Total Views: 105By : Editor Updated: 05-31-2024
From Stocks to Economy: Detailed Analysis of May 2024
Category: Markets Total Views: 99By : Editor Updated: 05-31-2024
FuelCell Energy Inc. (FCEL): Stock Opportunities & Risks
Category: Stocks Total Views: 132By : Editor Updated: 05-31-2024
Sector Rotation Strategies for 2024's Changing Economy
Category: Economy Total Views: 174By : Editor Updated: 05-31-2024
The Impact of Economic Changes on Small Businesses
Category: Business Total Views: 148By : Editor Updated: 05-31-2024
Investing in Dividend Stocks: Maximizing Income in 2024
Category: Investing Total Views: 141By : Editor Updated: 05-31-2024
Sun Belt Real Estate: Why It's the Hottest Market in 2024
Category: Real Estate Total Views: 157By : Editor Updated: 05-31-2024
Global Trade Dynamics: Opportunities and Challenges in 2024
Category: Economy Total Views: 186By : Editor Updated: 05-31-2024
Tilray Brands, Inc (TLRY): Stock Report - June 2024
Category: Stocks Total Views: 338By : Editor Updated: 05-30-2024